FDA NEWS

'Trust Drug' Oxytocin Unbelievable For Now - ABC News
Normally, this would not be a problem. Zak, a professor of economics and the founding director of the Center for Neuroeconomics Studies at Claremont Graduate University in Claremont, Calif., is generally happy to talk about his research, which
Source: www.abcnews.go.com

PanGenex (PGXC) Releases Shareholder and Operational Update - Forbes
PanGenex Corporation (Pink Sheets: PGXC), a publicly traded company, pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and
Source: www.forbes.com

Ranbaxy Gains Tentative Approval to Manufacture and Market - Forbes
PRINCETON, N.J., June 25 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets
Source: www.forbes.com

FDA: Merck can't market Gardasil to women 27-45 - Newsday
NEWARK, N.J. - Drug maker Merck says the Food and Drug Administration has rejected expanding the use of cervical cancer vaccine Gardasil to include women ages 27 to 45. The agency cited "issues that preclude approval" within the expected review
Source: www.newsday.com

House committee criticizes FDA over bonuses - Boston Globe
WASHINGTON— A review of bonuses paid to employees at the Food and Drug Administration showed many went to the agency's highest-paid staff rather than to the inspectors in the field, according to a review by the House Energy and Commerce Committee
Source: www.boston.com

Medicines hopeful on drug patent extension - MSN MoneyCentral
NEW YORK (AP) - Drug developer Medicines Co. could gain a patent extension on its blood thinner product Angiomax, following a measure by the House of Representatives earlier this week. In a Securities and Exchange Commission filing Tuesday, the
Source: moneycentral.msn.com

UPDATE 3-UCB to launch epilepsy drug in autumn, shares up - Reuters
BRUSSELS, June 27 (Reuters) - Shares in UCB SA (UCB.BR: Quote , Profile , Research , Stock Buzz ) jumped on Friday as the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn, after winning a green light
Source: www.reuters.com

Quark Pharmaceuticals Receives FDA Approval of IND for Kidney - Forbes
FREMONT, Calif., June 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney
Source: www.forbes.com

Vaccine help for kids on the way - Chicago Sun-Times
ATLANTA -- A federal advisory panel on Thursday endorsed two new combination vaccines designed to reduce the number of needle sticks that young children must endure to get the recommended immunizations. The panel gave its nod to a four-in-one shot
Source: www.suntimes.com